For your first-line patients with METex14 skipping NSCLC, choose METIME with TEPMETKO®1–3

Robust and lasting efficacy including tumor shrinkage in >90% of patients demonstrated in the largest clinical trial of patients with METex14 skipping NSCLC (N=313), confirmed with >18 months' follow-up*,**1–3

With TEPMETKO, give your patients more moments that matter

3–4% of your patients with NSCLC may have METex14 skipping4,5

Explore the importance of timely targeted therapy for your NSCLC patients

Explore the VISION trial

Learn more about the patient characteristics, efficacy outcomes and design of VISION, a single-arm, open-label, multicenter, non-randomized, multi-cohort study that analyzed patients with METex14 skipping NSCLC (N=313)1,2

TEPMETKO may offer substantially increased mDOR vs. capmatinib6

A matching-adjusted indirect comparison (MAIC) of TEPMETKO vs. capmatinib has shown improved mDOR, mOS and mPFS6

TEPMETKO is the only MET inhibitor with once-daily oral dosing†3

Limit the tablet burden while offering confirmed, long-term, robust and lasting efficacy for your patients with METex14 skipping NSCLC†,††2,3